A good example lies in the case of breast cancer exhibiting HER2 overexpression, for which the target therapy is trastuzumab, a monoclonal antibody that works by binding to the HER2 receptors on the surface of cancer cells, thereby inhibiting their growth and signaling pathways [8]. Here, ERBB2 is linked to breast carcinoma.